gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · NRXPHealthcarePharmaceuticals

NRX Pharmaceuticals, Inc. Common Stock (NRXP)

$2.49+11.16%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$2.47▼ 13.32% in range
Nov 3, 2025Low $1.68 · High $4.62Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

NRX Pharmaceuticals closed at $2.49 on Nov 4, up 11.16%, 46.1% below its 52-week closing high. Volume of 1.1M shares was 0.66× its 20-day average (below normal).

Split-adjusted performance: -15.3% over one month, -18.4% over six months, -12.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.10M, with a net margin of -1500.5%.

Short interest was 9.9M shares at the Oct 15 settlement, up 1.6% from the prior report (29.3% of float, 16.8 days to cover).

Market cap$107.8M43.3M shares
Revenue · quarter$1.1M—
Diluted EPS$-0.44—
P/E · TTM—P/S 31.8×
Net margin-1,500.5%Gross 38.7%
Dividend yieldNone
52-week range1.68 – 4.62−46.1% from high
Volume1.1M0.66× 20-day avg
Volatility · 60d61.5%Annualised
Short % of float29.3%16.8 days to cover
Net cash$26.3MCash $26.7M
Next earnings—Not scheduled
Split-adjusted performance
1W −7.4%1M −15.3%3M −19.4%6M −18.4%YTD −8.1%1Y −12.6%3Y −24.5%5Y −97.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum58
Revenue growth—
Net margin16
Value (low P/E)—
Size41

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short9.9M+1.6% vs prior
Days to cover16.8Settled Oct 15
% of float29.3%
Short vol. 10d59.7%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
NRXPNRX Pharmaceuticals$2.49+11.16%−18.4%—−1500.5%—$107.8M
IMUXImmunic$7.94+4.47%−27.9%———$108.3MCompare
HURATuHURA Biosciences$1.72+3.93%−32.3%———$109.6MCompare
EQEquillium$1.40−0.71%−35.5%———$109.7MCompare
OKUROnKure Therapeutics$2.59+3.60%−36.4%———$104.9MCompare
UNCYUnicycive Therapeutics$3.75+4.46%−53.9%———$104.5MCompare
ORGOOrganogenesis Holdings$0.8700+4.19%−66.0%−56.7%−227.0%—$111.9MCompare
ANIXAnixa Biosciences$3.28+7.37%+7.2%———$114.0MCompare
CATXPerspective Therapeutics$0.8702−1.11%−77.2%−72.1%−33069.1%—$99.3MCompare

News about NRX Pharmaceuticals

All news →
NRx Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · Sep 8, 2026▲ PositiveNRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common StockBenzinga · Jun 3, 2026NeutralNRx Pharmaceuticals (NRXP) Stock Fell 19% After Hours On Tuesday: Here's WhyBenzinga · Jun 3, 2026▼ NegativeNRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire Inc. · May 18, 2026▲ PositiveNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate UpdateGlobeNewswire Inc. · May 14, 2026▲ Positive

Quick answers

What does NRX Pharmaceuticals do?
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
What is NRXP's market cap?
$107.81M, based on the Nov 4 close of $2.49.
Does NRX Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of NRXP is sold short?
9.9M shares, 29.3% of float, as of Oct 15, 2026.
What sector is NRXP in?
Healthcare, in the Pharmaceuticals industry.

About NRX Pharmaceuticals

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

HQ: Wilmington, DE29 employeesListed May 25, 2021nrxpharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology